IP Library › Granted Patent US 9,550,755
Granted Patent B2
US 9,550,755 · App. 14/409,914 · Granted Jan 24, 2017

Complement pathway modulators and uses thereof

Inventors: Ulrich Hommel (Mulheim, DE); Edwige Liliane Jeanne Lorthiois (Niffer, FR); Jeurgen Klaus Maibaum (Weil-Haltingen, DE); Nils Ostermann (Binzen, DE); Stefan Andreas Randl (Frankfurt am Main, DE); Olivier Rogel (Hesingue, FR); Anna Vulpetti (Basel, CH)
Assignee: NOVARTIS AG
C07D403/14A61K31/416A61K31/4155A61K31/437A61K45/06C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,550,755
App. No.
14/409,914
Granted
Jan 24, 2017
Kind
B2
Abstract

The present invention provides a compound of formula I: a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Claims (14)

1. A compound, or salt thereof, represented by formula (V) or (VI):

wherein

Z 2 is CR 2 or N;

R 2 is hydrogen, C 1 -C 4 alkyl, or halogen;

R 3 is hydrogen, C 1 -C 4 alkyl, or pyrimidinylmethoxy;

R 5 is methyl or amino; and

R 10 is C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl-methyl or C 1 -C 2 haloalkyl.

2. The compound of claim 1 , or a salt thereof, selected from the group consisting of:

1-(2-oxo-2-((1R,3S,5R)-3-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)ethyl)-1H-indazole-3-carboxamide;

1-(2-oxo-2-((1R,3S,5R)-3-((1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)ethyl)-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;

(1R,3S,5R)-2-(2-(3-acetyl-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-2-azabicyclo[3.1.0] hexane-3-carboxamide; and

(1R,3S,5R)-N2-(1-carbamoyl-1H-indol-3-yl)-N3-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-2-azabicyclo[3.1.0] hexane-2,3-dicarboxamide.

3. The compound of claim 1 , or a salt thereof, which is 1-(2-((1R,3S,5R)-3-(1-isopropyl-1H-pyrazol-3-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazole-3-carboxamide.

4. A pharmaceutical composition comprising one or more pharmaceutically acceptable carriers and a therapeutically effective amount of a compound of claim 1 .

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2016
From: ROGEL, OLIVIER
To: NOVARTIS PHARMA AG
Reel/Frame 037868/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2016
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 037868/0304 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2015
From: ALTMANN, EVA; HOMMEL, ULRICH; LORTHIOIS, EDWIGE LILIANE JEANNE; MAIBAUM, JUERGEN KLAUS; OSTERMANN, NILS; QUANCARD, JEAN; VULPETTI, ANNA
To: NOVARTIS PHARMA AG
Reel/Frame 037238/0923 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2015
From: RANDL, STEFAN ANDREAS
To: NOVARTIS PHARMA AG
Reel/Frame 037239/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2015
From: ROGEL, OLIVIER
To: NOVARTIS PHARMA AG
Reel/Frame 037239/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2015
From: NOVARTIS PHARMA AG
To: NOVARTIS AG
Reel/Frame 037239/0244 →
Continuity (3)
Provisional Application 61670868 · Jul 12, 2012
Provisional Application 61774234 · Mar 7, 2013
Related Publication 20150148374A1 · May 28, 2015